Benchmark Research maintaining all operations and continuing to conduct investigational studies during the Covid-19 pandemic

Benchmark Research, a multi-year (VIE) Vaccine Industry Excellence Awards winner, is maintaining all operations and continuing to conduct investigational studies for the development of new vaccines and medicines along with our partners during the Covid-19 pandemic.

AUSTIN, Texas (PRWEB) April 03, 2020

All Benchmark Research clinical sites and call centers are working with Sponsors and CROs in following the CDC COVID-19 safety guidelines to ensure patient and employee safety while continuing to enroll subjects for ongoing studies during this pandemic. Having our own call center and extensive database of potential subjects positions our company to provide rapid support to any emergent novel research program addressing COVID-19 or related therapies.

Benchmark Research is a network of therapeutically diverse centers that specialize in vaccine research; since 1997 we have set the standard for excellence, having conducted more than 1063 studies and enrolled in excess of 38,000 subjects. Our partners can be assured we are prepared to meet all our obligations while maintaining safety during this unprecedented event.

With corporate offices located in Austin, Texas, the company operates sites in Texas, (2 in Austin) (Fort Worth) (San Angelo), Louisiana (Metairie) (Covington), and California (Sacramento)

Sponsors and CROs interested in learning more about Benchmark Research, please contact Van Johnson, Executive Director of Business Development

vanjohnson@benchmarkresearch.net or 469.854.029

For the original version on PRWeb visit: https://www.prweb.com/releases/benchmark_research_maintaining_all_operations_and_continuing_to_conduct_investigational_studies_during_the_covid_19_pandemic/prweb17023173.htm